Please assess the completion status of the following clinical trial:

Trial Title: Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- primary Addison's disease in combination with long-standing Type 1 diabetes~Exclusion Criteria:~* cardiovascular disease~* active malignant disease~* pregnant women~* pharmacological treatment with glucocorticoids or drugs that interfere with cortisol metabolism (antiepileptics, rifampicin, St. Johns war, estrogens)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cortef (Type: ACTIVE_COMPARATOR): Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
- Solu-cortef (Type: ACTIVE_COMPARATOR): This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).